KRTAP19-3 inhibitors represent a class of chemical compounds designed to specifically modulate the function or expression of keratin-associated protein 19-3 (KRTAP19-3). KRTAP proteins, including KRTAP19-3, are integral to the structure of hair and other keratinized tissues, where they interact with keratin filaments to form a robust and resilient matrix. Inhibitors targeting KRTAP19-3 are molecules that may either bind directly to the protein or interfere with its synthesis, stability, or regulatory pathways, thereby modulating the integrity of keratinized structures. These inhibitors can function by altering the assembly or disassembly of keratin filament networks, leading to changes in the mechanical properties of hair and skin. Due to the structural role of KRTAP19-3 in the keratin matrix, inhibitors of this protein could have wide-ranging effects on the physical characteristics of keratinized tissues.
The chemical nature of KRTAP19-3 inhibitors can vary significantly, but many are small molecules that operate by targeting specific molecular domains within the protein or its regulatory elements. Some inhibitors may work by blocking protein-protein interactions crucial for keratin filament stabilization, while others might interfere with post-translational modifications of KRTAP19-3, such as phosphorylation or glycosylation, that are essential for its function. By modulating the availability or functionality of KRTAP19-3, these inhibitors provide a tool to study the structural dynamics of keratinized tissues, such as hair, nails, and the outermost layers of the skin. Additionally, such compounds may be used to dissect the role of KRTAP proteins in various physiological processes, offering insights into the fundamental biology of keratin-associated proteins and their interactions within keratinocyte cells.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound could hypothetically demethylate the promoter region of KRTAP19-3, potentially leading to transcriptional silencing of the gene. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
By inhibiting histone deacetylase, Trichostatin A might enhance histone acetylation, possibly resulting in the condensed chromatin structure that is less conducive to KRTAP19-3 transcription. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid may lead to hyperacetylation of histones associated with the KRTAP19-3 gene, potentially reducing the transcriptional activity of this gene. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
RG 108 might prevent methylation of the KRTAP19-3 gene promoter, which could result in decreased expression of the gene. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine could lead to the reduction of DNA methylation levels at the KRTAP19-3 locus, possibly leading to downregulation of its expression. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
MS-275 may selectively inhibit histone deacetylases associated with the KRTAP19-3 gene, which could result in lower levels of its mRNA. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 could inhibit PI3K, potentially leading to a decrease in AKT pathway activity and subsequent downregulation of KRTAP19-3 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 may inhibit the MEK/ERK branch of the MAPK pathway, which could result in the decreased expression of KRTAP19-3. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
By inhibiting the proteasome, Bortezomib could cause the accumulation of misfolded proteins, potentially leading to cellular stress and reduced KRTAP19-3 expression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 could disrupt the interaction between BET bromodomains and acetylated histones, potentially leading to the downregulation of KRTAP19-3 expression. | ||||||